Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus

Phonphimon Wongthida, Rosa Maria Diaz, Christine Pulido, Diana Rommelfanger, Feorillo Galivo, Karen Kaluza, Timothy Kottke, Jill Thompson, Alan Melcher, Richard Geoffrey Vile

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

We have shown that the antitumor activity of vesicular stomatitis virus (VSV) against B16ova tumors in C57BL/6 mice is predominantly due to innate antiviral immune effectors. We have also shown that the innate immune-activating properties of VSV can be harnessed to prime adaptive T-cell responses against a tumor-associated antigen (TAA) if the virus is engineered to express the cDNA of the antigen. Here, we show that the combination of VSV expressing OVA as a model tumor antigen, along with adoptive T-cell therapy targeted against the same antigen, is superior to either treatment alone and induces systemic antitumor activity. In addition, we extend our findings with the OVA model to the therapeutic use of VSV expressing hgp100, a self TAA against which tolerance is well established in C57BL/6 mice. In contrast to VSV-ova, T-cell responses raised by VSV-hgp100 were insufficient to improve therapy against B16ova tumors compared with VSV-GFP alone. However, in combination with adoptive transfer of gp100-specific pmel T cells, intratumoral VSV-hgp100 cured significantly more mice than either virus or T cells alone. Even in an aggressive model of metastatic disease, antitumor therapy was generated at levels similar to those observed in the VSV-ova/OT-I model in which a potently immunogenic, nonself TAA was targeted. Therefore, individual poorly effective virotherapies and T-cell therapies that target self TAA of low immunogenicity, which reflects the situation in patients, can be combined to generate very effective antitumor therapy.

Original languageEnglish (US)
Pages (from-to)1343-1353
Number of pages11
JournalHuman Gene Therapy
Volume22
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Oncolytic Virotherapy
Vesicular Stomatitis
Autoantigens
Neoplasm Antigens
Immunity
Viruses
T-Lymphocytes
Cell- and Tissue-Based Therapy
Inbred C57BL Mouse
Ovum
Satellite Viruses
Antigens
Adoptive Transfer
Therapeutic Uses
Therapeutics
Antiviral Agents
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. / Wongthida, Phonphimon; Diaz, Rosa Maria; Pulido, Christine; Rommelfanger, Diana; Galivo, Feorillo; Kaluza, Karen; Kottke, Timothy; Thompson, Jill; Melcher, Alan; Vile, Richard Geoffrey.

In: Human Gene Therapy, Vol. 22, No. 11, 01.11.2011, p. 1343-1353.

Research output: Contribution to journalArticle

Wongthida, P, Diaz, RM, Pulido, C, Rommelfanger, D, Galivo, F, Kaluza, K, Kottke, T, Thompson, J, Melcher, A & Vile, RG 2011, 'Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus', Human Gene Therapy, vol. 22, no. 11, pp. 1343-1353. https://doi.org/10.1089/hum.2010.216
Wongthida, Phonphimon ; Diaz, Rosa Maria ; Pulido, Christine ; Rommelfanger, Diana ; Galivo, Feorillo ; Kaluza, Karen ; Kottke, Timothy ; Thompson, Jill ; Melcher, Alan ; Vile, Richard Geoffrey. / Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. In: Human Gene Therapy. 2011 ; Vol. 22, No. 11. pp. 1343-1353.
@article{7180cb41d5874ce1b0793f0bbdcb7b1b,
title = "Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus",
abstract = "We have shown that the antitumor activity of vesicular stomatitis virus (VSV) against B16ova tumors in C57BL/6 mice is predominantly due to innate antiviral immune effectors. We have also shown that the innate immune-activating properties of VSV can be harnessed to prime adaptive T-cell responses against a tumor-associated antigen (TAA) if the virus is engineered to express the cDNA of the antigen. Here, we show that the combination of VSV expressing OVA as a model tumor antigen, along with adoptive T-cell therapy targeted against the same antigen, is superior to either treatment alone and induces systemic antitumor activity. In addition, we extend our findings with the OVA model to the therapeutic use of VSV expressing hgp100, a self TAA against which tolerance is well established in C57BL/6 mice. In contrast to VSV-ova, T-cell responses raised by VSV-hgp100 were insufficient to improve therapy against B16ova tumors compared with VSV-GFP alone. However, in combination with adoptive transfer of gp100-specific pmel T cells, intratumoral VSV-hgp100 cured significantly more mice than either virus or T cells alone. Even in an aggressive model of metastatic disease, antitumor therapy was generated at levels similar to those observed in the VSV-ova/OT-I model in which a potently immunogenic, nonself TAA was targeted. Therefore, individual poorly effective virotherapies and T-cell therapies that target self TAA of low immunogenicity, which reflects the situation in patients, can be combined to generate very effective antitumor therapy.",
author = "Phonphimon Wongthida and Diaz, {Rosa Maria} and Christine Pulido and Diana Rommelfanger and Feorillo Galivo and Karen Kaluza and Timothy Kottke and Jill Thompson and Alan Melcher and Vile, {Richard Geoffrey}",
year = "2011",
month = "11",
day = "1",
doi = "10.1089/hum.2010.216",
language = "English (US)",
volume = "22",
pages = "1343--1353",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus

AU - Wongthida, Phonphimon

AU - Diaz, Rosa Maria

AU - Pulido, Christine

AU - Rommelfanger, Diana

AU - Galivo, Feorillo

AU - Kaluza, Karen

AU - Kottke, Timothy

AU - Thompson, Jill

AU - Melcher, Alan

AU - Vile, Richard Geoffrey

PY - 2011/11/1

Y1 - 2011/11/1

N2 - We have shown that the antitumor activity of vesicular stomatitis virus (VSV) against B16ova tumors in C57BL/6 mice is predominantly due to innate antiviral immune effectors. We have also shown that the innate immune-activating properties of VSV can be harnessed to prime adaptive T-cell responses against a tumor-associated antigen (TAA) if the virus is engineered to express the cDNA of the antigen. Here, we show that the combination of VSV expressing OVA as a model tumor antigen, along with adoptive T-cell therapy targeted against the same antigen, is superior to either treatment alone and induces systemic antitumor activity. In addition, we extend our findings with the OVA model to the therapeutic use of VSV expressing hgp100, a self TAA against which tolerance is well established in C57BL/6 mice. In contrast to VSV-ova, T-cell responses raised by VSV-hgp100 were insufficient to improve therapy against B16ova tumors compared with VSV-GFP alone. However, in combination with adoptive transfer of gp100-specific pmel T cells, intratumoral VSV-hgp100 cured significantly more mice than either virus or T cells alone. Even in an aggressive model of metastatic disease, antitumor therapy was generated at levels similar to those observed in the VSV-ova/OT-I model in which a potently immunogenic, nonself TAA was targeted. Therefore, individual poorly effective virotherapies and T-cell therapies that target self TAA of low immunogenicity, which reflects the situation in patients, can be combined to generate very effective antitumor therapy.

AB - We have shown that the antitumor activity of vesicular stomatitis virus (VSV) against B16ova tumors in C57BL/6 mice is predominantly due to innate antiviral immune effectors. We have also shown that the innate immune-activating properties of VSV can be harnessed to prime adaptive T-cell responses against a tumor-associated antigen (TAA) if the virus is engineered to express the cDNA of the antigen. Here, we show that the combination of VSV expressing OVA as a model tumor antigen, along with adoptive T-cell therapy targeted against the same antigen, is superior to either treatment alone and induces systemic antitumor activity. In addition, we extend our findings with the OVA model to the therapeutic use of VSV expressing hgp100, a self TAA against which tolerance is well established in C57BL/6 mice. In contrast to VSV-ova, T-cell responses raised by VSV-hgp100 were insufficient to improve therapy against B16ova tumors compared with VSV-GFP alone. However, in combination with adoptive transfer of gp100-specific pmel T cells, intratumoral VSV-hgp100 cured significantly more mice than either virus or T cells alone. Even in an aggressive model of metastatic disease, antitumor therapy was generated at levels similar to those observed in the VSV-ova/OT-I model in which a potently immunogenic, nonself TAA was targeted. Therefore, individual poorly effective virotherapies and T-cell therapies that target self TAA of low immunogenicity, which reflects the situation in patients, can be combined to generate very effective antitumor therapy.

UR - http://www.scopus.com/inward/record.url?scp=80052507771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052507771&partnerID=8YFLogxK

U2 - 10.1089/hum.2010.216

DO - 10.1089/hum.2010.216

M3 - Article

C2 - 21366404

AN - SCOPUS:80052507771

VL - 22

SP - 1343

EP - 1353

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 11

ER -